DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.
Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, Maloy MA, Devlin SM, Batlevi CL, Shah GL, Scordo M, Palomba ML, Dahi PB, Sauter CS, Santomasso BD, Mead E, Perales MA.
Wudhikarn K, et al. Among authors: maloy ma.
Blood Adv. 2020 Jul 14;4(13):3024-3033. doi: 10.1182/bloodadvances.2020001972.
Blood Adv. 2020.
PMID: 32614964
Free PMC article.